LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Accurately Predicts Cancer Outcomes from Tissue Samples

By LabMedica International staff writers
Posted on 27 Dec 2023
Print article
Image: The AI model analyzes cell spatial organization to make patient diagnoses and prognoses (Photo courtesy of UT Southwestern)
Image: The AI model analyzes cell spatial organization to make patient diagnoses and prognoses (Photo courtesy of UT Southwestern)

Patient tissue samples are commonly examined on slides by pathologists, a process integral to diagnosis. This traditional method, while effective, is notably time-intensive and subject to variability in interpretations among different pathologists. Moreover, some subtle details in pathology images might escape human observation but could hold critical insights into a patient's health status. Over recent years, several artificial intelligence (AI) models have been developed to undertake certain tasks typically performed by pathologists, such as classifying cell types or gauging cellular interactions based on proximity. Nevertheless, these models have not fully captured the more intricate aspects of tissue image analysis that pathologists conduct, including recognizing complex cell spatial arrangements and filtering out irrelevant image 'noise' that could distort interpretations. Addressing this gap, researchers have now introduced an innovative AI model that is capable of examining the spatial organization of cells within tissue samples, offering precise predictions about cancer patient outcomes and offering new prospects for AI-assisted cancer prognosis and tailored treatment plans.

Dubbed Ceograph, this AI tool, created by researchers at UT Southwestern Medical Center (Dallas, TX, USA), mimics the approach taken by pathologists for examining tissue slides. It begins by identifying cells and their respective positions within the image. It then classifies cell types and delineates their shapes and spatial distributions, creating a comprehensive map where the arrangement, dispersion, and interactions among cells are detailed for analysis. The team validated Ceograph in three clinical scenarios using pathology slides. In one instance, Ceograph distinguished between two lung cancer types: adenocarcinoma and squamous cell carcinoma. In another, it gauged the progression risk of potentially cancerous oral conditions to malignancy. Finally, it identified lung cancer patients most likely to benefit from epidermal growth factor receptor inhibitors.

In each scenario, Ceograph's performance in predicting patient outcomes surpassed traditional methods. Notably, the cell spatial organization insights provided by Ceograph are not only interpretable but also shed light on the biological implications of varying individual cell-cell spatial interactions. These developments highlight the increasingly vital role AI can play in healthcare, particularly in enhancing the precision and efficiency of pathology analyses. This technology promises to refine preventive strategies for individuals at high risk and tailor treatment choices to meet each patient's unique needs.

“Cell spatial organization is like a complex jigsaw puzzle where each cell serves as a unique piece, fitting together meticulously to form a cohesive tissue or organ structure,” said study leader Guanghua Xiao, Ph.D. “This research showcases the remarkable ability of AI to grasp these intricate spatial relationships among cells within tissues, extracting subtle information previously beyond human comprehension while predicting patient outcomes.”

Related Links:
UT Southwestern Medical Center 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.